DehydrocrenatidineCAS# 65236-62-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 65236-62-6 | SDF | Download SDF |
| PubChem ID | 5318875 | Appearance | Yellow powder |
| Formula | C15H14N2O2 | M.Wt | 254.3 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 1-ethenyl-4,8-dimethoxy-9H-pyrido[3,4-b]indole | ||
| SMILES | COC1=CC=CC2=C1NC3=C2C(=CN=C3C=C)OC | ||
| Standard InChIKey | LDWBTKDUAXOZRB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H14N2O2/c1-4-10-15-13(12(19-3)8-16-10)9-6-5-7-11(18-2)14(9)17-15/h4-8,17H,1H2,2-3H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Dehydrocrenatidine is a JAK-specific inhibitor, can inhibit JAK-STAT3-dependent DU145 and MDA-MB-468 cell survival and induce cell apoptosis. 2. Dehydrocrenatidine inhibits JAK2-JH1 kinase activity in vitro , represses constitutively activated JAK2 and STAT3, as well as interleukin-6-, interferon-α-, and interferon-γ-stimulated JAK activity, and STAT phosphorylation, and suppresses STAT3 and STAT1 downstream gene expression. |
| Targets | JAK | STAT | IL Receptor |
Dehydrocrenatidine Dilution Calculator
Dehydrocrenatidine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.9324 mL | 19.6618 mL | 39.3236 mL | 78.6473 mL | 98.3091 mL |
| 5 mM | 0.7865 mL | 3.9324 mL | 7.8647 mL | 15.7295 mL | 19.6618 mL |
| 10 mM | 0.3932 mL | 1.9662 mL | 3.9324 mL | 7.8647 mL | 9.8309 mL |
| 50 mM | 0.0786 mL | 0.3932 mL | 0.7865 mL | 1.5729 mL | 1.9662 mL |
| 100 mM | 0.0393 mL | 0.1966 mL | 0.3932 mL | 0.7865 mL | 0.9831 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- N-Glyceryltaurine
Catalog No.:BCN1753
CAS No.:65222-42-6
- Gossypin
Catalog No.:BCN7987
CAS No.:652-78-8
- Isosorbide
Catalog No.:BCC4667
CAS No.:652-67-5
- Avermectin B1b
Catalog No.:BCC1383
CAS No.:65195-56-4
- Avermectin B1a
Catalog No.:BCC1382
CAS No.:65195-55-3
- (16R)-E-Isositsirikine
Catalog No.:BCN4000
CAS No.:6519-27-3
- (16R)-Dihydrositsirikine
Catalog No.:BCN4195
CAS No.:6519-26-2
- 4'-Hydroxyflavanone
Catalog No.:BCN6548
CAS No.:6515-37-3
- 7-Hydroxyflavanone
Catalog No.:BCN6539
CAS No.:6515-36-2
- Elastase Inhibitor, SPCK
Catalog No.:BCC1226
CAS No.:65144-34-5
- Nicorandil
Catalog No.:BCC5004
CAS No.:65141-46-0
- N-Methylcorydaldine
Catalog No.:BCN3300
CAS No.:6514-05-2
- Cucurbitacin B 2-O-beta-D-glucoside
Catalog No.:BCN3119
CAS No.:65247-27-0
- Arvenin II
Catalog No.:BCN7878
CAS No.:65247-28-1
- Ketoconazole
Catalog No.:BCC2272
CAS No.:65277-42-1
- Calhex 231 hydrochloride
Catalog No.:BCC7931
CAS No.:652973-93-8
- Primulic Acid 1
Catalog No.:BCC8236
CAS No.:65312-86-9
- L-Norgestrel
Catalog No.:BCC9105
CAS No.:797-64-8
- Scopolamine hydrobromide trihydrate
Catalog No.:BCC8188
CAS No.:6533-68-2
- Demethylvestitol
Catalog No.:BCN4079
CAS No.:65332-45-8
- 2,6-Tropanediol
Catalog No.:BCN1875
CAS No.:65356-02-7
- H-D-Pro-OMe.HCl
Catalog No.:BCC3025
CAS No.:65365-28-8
- D-Chicoric Acid
Catalog No.:BCC8148
CAS No.:52248-48-3
- alpha-Isowighteone
Catalog No.:BCN4197
CAS No.:65388-03-6
Dehydrocrenatidine is a novel janus kinase inhibitor.[Pubmed:25583084]
Mol Pharmacol. 2015 Apr;87(4):572-81.
Janus kinase (JAK) 2 plays a pivotal role in the tumorigenesis of signal transducers and activators of transcription (STAT) 3 constitutively activated solid tumors. JAK2 mutations are involved in the pathogenesis of various types of hematopoietic disorders, such as myeloproliferative disorders, polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Thus, small-molecular inhibitors targeting JAK2 are potent for therapy of these diseases. In this study, we screened 1,062,608 drug-like molecules from the ZINC database and 2080 natural product chemicals. We identified a novel JAK family kinase inhibitor, Dehydrocrenatidine, that inhibits JAK-STAT3-dependent DU145 and MDA-MB-468 cell survival and induces cell apoptosis. Dehydrocrenatidine represses constitutively activated JAK2 and STAT3, as well as interleukin-6-, interferon-alpha-, and interferon-gamma-stimulated JAK activity, and STAT phosphorylation, and suppresses STAT3 and STAT1 downstream gene expression. Dehydrocrenatidine inhibits JAKs-JH1 domain overexpression-induced STAT3 and STAT1 phosphorylation. In addition, Dehydrocrenatidine inhibits JAK2-JH1 kinase activity in vitro. Importantly, Dehydrocrenatidine does not show significant effect on Src overexpression and epidermal growth factor-induced STAT3 activation. Our results indicate that Dehydrocrenatidine is a JAK-specific inhibitor.
